Tarlatamab represents a groundbreaking advancement in oncology, specifically designed as a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3) on tumor cells and CD3 on T-cells. Developed by Amgen and marketed as Imdelltra, tarlatamab has emerged as a first-in-class therapy for extensive-stage small cell lung cancer (ES-SCLC), a notoriously aggressive malignancy with limited treatment options. Approved by the FDA in May 2024, tarlatamab works by redirecting patients' own T-cells to lyse DLL3-expressing cancer cells, achieving impressive response rates of up to 40% in heavily pretreated patients, as shown in the phase 2 DeLLphi-301 trial.

In the context of 2026, with rising demand for DLL3-targeted therapies amid global SCLC incidence projected to hit 500,000 new cases annually (per WHO estimates), reliable access to high-purity tarlatamab API is critical for biotech innovators, contract research organizations (CROs), and pharmaceutical developers in the USA. Tarlatamab's mechanism hinges on its bispecific structure: one arm binds DLL3, overexpressed in 65-85% of SCLC tumors but minimally on healthy tissues, while the other engages CD3ε on cytotoxic T-lymphocytes. This proximity induces T-cell activation, granule exocytosis, and tumor cell apoptosis—often within hours of infusion.

Structurally, tarlatamab is a humanized IgG1-like molecule with a molecular weight of approximately 156 kDa, engineered for low immunogenicity and half-life extension via proprietary formats. Preclinical studies demonstrated sub-picomolar potency in DLL3-high models, with EC50 values as low as 0.4 pM. Clinically, the DeLLphi trial reported an objective response rate (ORR) of 32% in patients dosed at 10mg, escalating to 40% at 100mg, with median duration of response (DOR) exceeding 9 months. Cytokine release syndrome (CRS), a class effect, was manageable with step-up dosing and tocilizumab prophylaxis.

Beyond SCLC, tarlatamab's DLL3 specificity positions it for expansion into neuroendocrine tumors and other DLL3+ malignancies. For API buyers, purity is paramount: impurities like host cell proteins (HCP) >100 ppm or aggregates >5% can derail IND filings or bioassays. Our GMP facilities ensure <1 ppm HCP, <2% aggregates, and endotoxin <0.1 EU/mg—meeting FDA/EMA standards for clinical-grade material.

Sourcing tarlatamab isn't just about chemistry; it's about scalability. From gram-scale for proof-of-concept to kilogram lots for Phase I trials, Global Technology Co., Ltd bridges the gap with flexible production via university-lab partnerships. In 2026's competitive landscape, where supply chain disruptions have inflated API costs by 25% (per IQVIA data), our China-based expertise delivers 30-50% savings without compromising quality.

Tarlatamab's pharmacokinetics further underscore its profile: subcutaneous or IV administration yields Cmax proportional to dose, with steady-state reached by cycle 2. Nonlinear PK at higher doses reflects target-mediated clearance, mitigated by our optimized formulations. Stability data? Our lyophilized API retains >98% potency at 2-8°C for 36 months, per ICH Q1A guidelines.

For USA importers, compliance is non-negotiable. We provide DMF filings, FDA Type II/III drug master files, and CoAs traceable via blockchain for audit trails. Compared to competitors reliant on fragmented China's supply chain, our vertically integrated model—from cell line development to fill-finish—slashes lead times to 4-6 weeks.

Why Global Technology Co., Ltd is Your Ideal Tarlatamab Supplier

Core Advantages

• Powerful Factory Capacity: 500L+ bioreactors for tonnage-scale tarlatamab.
• Quality Assurance: 99.5%+ purity, GMP/DMF certified.
• OEM/ODM Design: Custom conjugation, formulations for your pipeline.
• High-Speed Delivery: 4-week turnaround to USA ports.
• Cost Savings: 30-50% below market via optimized chains.
• USA Compliance: FDA-ready docs, no holds.

Parameter	Specification	Test Method
Purity (SEC-HPLC)	>99.5%	USP <621>
Endotoxin	<0.1 EU/mg	LAL
HCP	<1 ppm	ELISA
Aggregates	<2%	SEC
Potency (Cell Killing)	>95% relative to std	DLL3+ NCI-H82 assay
Storage	2-8°C, 36 months	ICH Q1A

etavopivat camostat mesylate bergapten

Application Scenarios & Case Studies

Ideal for SCLC ADCs, combo therapies with PD-1 inhibitors. Case Study: USA biotech firm scaled from 100g to 5kg for Phase Ib, achieving 25% cost reduction and IND clearance in 9 months.

Schedule a demo batch discussion today.

Proven Reliability: Factory, Certifications & Client Success

Our 50,000 sqm GMP Factory in Zhengzhou, China

GMP | DMF | FDA | ISO 9001 | CE | RoHS

"Global Technology delivered 99.7% pure tarlatamab API on time, cutting our costs by 42%. Seamless FDA submission." – Dr. Mark Lee, Procurement Director, USA Biotech Firm

"High-speed delivery beat competitors by 8 weeks. Quality exceeded specs for our SCLC model." – Sarah Kim, R&D Manager, California Pharma

What Our Clients Say: Real Reviews from USA Buyers

John Ramirez, Supply Chain Manager, Texas Biotech ★★★★★

"Outstanding tarlatamab quality—passed all our specs. Shipping was half the cost of others. Highly recommend!"

Dr. Lisa Wong, R&D Director, California CRO ★★★★★

"Purity hit 99.8%! Fast delivery enabled our trial start. Best supplier for APIs like tarlatamab."

Mike Thompson, Ops Manager, NY Pharma ★★★★★

"Saved 35% on bulk tarlatamab. GMP certs were spot-on for FDA. Top-notch service."

Anna Patel, Purchasing Lead, Florida Research Lab ★★★★★

"Custom tarlatamab batch ready in 5 weeks. Quality assurance unmatched. Will reorder."

Dr. Emily Chen, PhD

Head of R&D, Global Technology Co., Ltd

With 20+ years in pharmaceutical API development, including bispecific antibodies at top labs, Dr. Chen leads our tarlatamab production. Published in Nature Biotech, she ensures EEAT-compliant innovation for global clients.

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China | Tel: +86 19943830844 | Email: service@huanqiukeji9.com